Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

53.688  -0.24 (-0.45%)

Fundamental Rating

8

HALO gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making HALO a very profitable company, without any liquidiy or solvency issues. HALO is evaluated to be cheap and growing strongly. This does not happen too often! This makes HALO very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
In the past year HALO had a positive cash flow from operations.
In the past 5 years HALO has always been profitable.
In the past 5 years HALO always reported a positive cash flow from operatings.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO has a better Return On Assets (22.10%) than 98.57% of its industry peers.
With an excellent Return On Equity value of 100.64%, HALO belongs to the best of the industry, outperforming 99.47% of the companies in the same industry.
The Return On Invested Capital of HALO (23.44%) is better than 98.40% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 15.87%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(23.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROIC 23.44%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

With an excellent Profit Margin value of 44.76%, HALO belongs to the best of the industry, outperforming 98.75% of the companies in the same industry.
HALO's Profit Margin has declined in the last couple of years.
The Operating Margin of HALO (55.10%) is better than 99.82% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
Looking at the Gross Margin, with a value of 83.45%, HALO belongs to the top of the industry, outperforming 86.45% of the companies in the same industry.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for HALO has been reduced compared to 5 years ago.
The debt/assets ratio for HALO has been reduced compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

HALO has an Altman-Z score of 4.63. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.63, HALO belongs to the best of the industry, outperforming 80.04% of the companies in the same industry.
The Debt to FCF ratio of HALO is 3.04, which is a good value as it means it would take HALO, 3.04 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HALO (3.04) is better than 94.12% of its industry peers.
A Debt/Equity ratio of 3.13 is on the high side and indicates that HALO has dependencies on debt financing.
HALO has a Debt to Equity ratio of 3.13. This is amonst the worse of the industry: HALO underperforms 83.42% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Altman-Z 4.63
ROIC/WACC2.55
WACC9.18%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 8.39 indicates that HALO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.39, HALO is in the better half of the industry, outperforming 74.15% of the companies in the same industry.
A Quick Ratio of 7.30 indicates that HALO has no problem at all paying its short term obligations.
HALO's Quick ratio of 7.30 is fine compared to the rest of the industry. HALO outperforms 69.88% of its industry peers.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 7.3
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.77%, which is quite impressive.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.66%.
Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.06% yearly.
The Revenue is expected to grow by 11.27% on average over the next years. This is quite good.
EPS Next Y26.02%
EPS Next 2Y28.66%
EPS Next 3Y26.73%
EPS Next 5Y16.06%
Revenue Next Year24.83%
Revenue Next 2Y21.37%
Revenue Next 3Y18.42%
Revenue Next 5Y11.27%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 11.80 indicates a reasonable valuation of HALO.
96.79% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
HALO's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.03.
Based on the Price/Forward Earnings ratio of 7.67, the valuation of HALO can be described as very cheap.
97.50% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.94. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.8
Fwd PE 7.67
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.61% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaply inside the industry as 96.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.38
EV/EBITDA 10.09
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as HALO's earnings are expected to grow with 26.73% in the coming years.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y28.66%
EPS Next 3Y26.73%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/22/2025, 12:29:48 PM)

53.688

-0.24 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners99.23%
Inst Owner Change-0.69%
Ins Owners0.81%
Ins Owner Change0.96%
Market Cap6.63B
Analysts77.33
Price Target70.96 (32.17%)
Short Float %7.75%
Short Ratio5.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)6.64%
Max EPS beat(2)16.18%
EPS beat(4)4
Avg EPS beat(4)16.82%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)11.93%
EPS beat(12)10
Avg EPS beat(12)11.5%
EPS beat(16)13
Avg EPS beat(16)12.47%
Revenue beat(2)2
Avg Revenue beat(2)7.09%
Min Revenue beat(2)1.36%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.53%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)4.78%
Revenue beat(12)7
Avg Revenue beat(12)3.03%
Revenue beat(16)9
Avg Revenue beat(16)3.86%
PT rev (1m)2.69%
PT rev (3m)7.45%
EPS NQ rev (1m)3.51%
EPS NQ rev (3m)1.87%
EPS NY rev (1m)0.98%
EPS NY rev (3m)6.67%
Revenue NQ rev (1m)0.72%
Revenue NQ rev (3m)0.74%
Revenue NY rev (1m)4.76%
Revenue NY rev (3m)5.54%
Valuation
Industry RankSector Rank
PE 11.8
Fwd PE 7.67
P/S 6.12
P/FCF 13.38
P/OCF 13.16
P/B 13.75
P/tB N/A
EV/EBITDA 10.09
EPS(TTM)4.55
EY8.47%
EPS(NY)7
Fwd EY13.04%
FCF(TTM)4.01
FCFY7.48%
OCF(TTM)4.08
OCFY7.6%
SpS8.78
BVpS3.9
TBVpS-2.58
PEG (NY)0.45
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROCE 29.2%
ROIC 23.44%
ROICexc 36.94%
ROICexgc 96.44%
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
FCFM 45.72%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Debt/EBITDA 2.22
Cap/Depr 9.93%
Cap/Sales 0.75%
Interest Coverage 250
Cash Conversion 74.2%
Profit Quality 102.14%
Current Ratio 8.39
Quick Ratio 7.3
Altman-Z 4.63
F-Score9
WACC9.18%
ROIC/WACC2.55
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
EPS Next Y26.02%
EPS Next 2Y28.66%
EPS Next 3Y26.73%
EPS Next 5Y16.06%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%
Revenue Next Year24.83%
Revenue Next 2Y21.37%
Revenue Next 3Y18.42%
Revenue Next 5Y11.27%
EBIT growth 1Y56.46%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year42.78%
EBIT Next 3Y32.05%
EBIT Next 5Y15.57%
FCF growth 1Y88.07%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y80.4%
OCF growth 3Y16.96%
OCF growth 5YN/A